Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type (Q37895257)

24 August 2017

1 reference

title

Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type (English)

1 reference

24 August 2017

0 references

0 references

1

Sohita Dhillon

1 reference

24 August 2017

publication date

1 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

71

1 reference

24 August 2017

issue

9

1 reference

24 August 2017

page(s)

1209-1231

1 reference

A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

EFNS guidelines for the diagnosis and management of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Rivastigmine transdermal patch: role in the management of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Rationale for transdermal drug administration in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Inhibition of human cholinesterases by drugs used to treat Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Rivastigmine in the treatment of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Rivastigmine exposure provided by a transdermal patch versus capsules.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206380-000000000-00000

Relative tolerability of Alzheimer's disease treatments

21 January 2018

1 reference

12 December 2020

Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease

1 reference

12 December 2020

Clinical practice. Early Alzheimer's disease

1 reference

12 December 2020

Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications

1 reference

12 December 2020

American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition

1 reference

12 December 2020

Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application

1 reference

12 December 2020

Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results

1 reference

12 December 2020

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

1 reference

12 December 2020

10.2165/11206380-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1025381639

0 references

1 reference